All In Biotech

Drug Trial Radar · NCT06757634

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib With Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,180

Planned (sponsor's estimate)

Start

Jul 24, 2025

Primary completion

Mar 31, 2029

Study completion Jul 30, 2033

Sponsor

Lead sponsor
Celcuity IncIndustry
Sponsor type
Industry
First posted
Jan 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

Conditions

  • Breast Cancer

Interventions

  • Arm A: Gedatolisib + Palbociclib + FulvestrantDrug

    Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off Other Names: • PF-05212384 Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle. Other Names: • IBRANCE Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant every 2 weeks during Cycle 1 and then every 4 weeks Other Names: • Faslodex

  • Arm B: Ribociclib + FulvestrantDrug

    Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle Other Names: • KISQALI® Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant approximately every 2 weeks during Cycle 1 then approximately every 4 weeks Other Names: • Faslodex

  • Arm C: Gedatolisib + Palbociclib + LetrozoleDrug

    Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle. Drug: Letrozole Participants will receive oral letrozole daily.

  • Arm D: Ribociclib + LetrozoleDrug

    Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle Drug: Letrozole Participants will receive oral letrozole daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From date of randomization to the date of death due to any cause, up to approximately 48 months

Locations

239 sites in 25 countries. Site status is shown where the registry gives one.

  • St Bernards Medical Center

    Jonesboro, Arkansas · Not yet recruiting

  • CARTI Cancer Center

    Little Rock, Arkansas · Not yet recruiting

  • City of Hope Medical Center

    Duarte, California · Not yet recruiting

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • UCLA Hematology Oncology Santa Monica

    Los Angeles, California · Recruiting

  • Cancer Care Associates

    Redondo Beach, California · Not yet recruiting

  • UC San Diego Moores Cancer Center

    San Diego, California · Not yet recruiting

  • University of Colorado Hospital - Cancer Center

    Aurora, Colorado · Not yet recruiting

  • BRCR Medical Center, Inc- Internal Medicine

    Plantation, Florida · Recruiting

  • BRCR Medical Center, INC

    Tamarac, Florida · Recruiting

  • The University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • Mercy Health-Paducah Cancer Center

    Paducah, Kentucky · Recruiting

  • American Oncology Partners, P.A.

    Bethesda, Maryland · Withdrawn

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts · Not yet recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Saint Luke's Cancer Institute

    Kansas City, Missouri · Recruiting

  • Washington University School of Medicine in Saint Louis

    St Louis, Missouri · Recruiting

  • SCL Health - Cancer Centers of Montana

    Billings, Montana · Recruiting

  • Christus Saint Vincent Regional Cancer Center

    Santa Fe, New Mexico · Not yet recruiting

  • Weill Cornell Medical College - NewYork-Presbyterian Hospital

    New York, New York · Recruiting

  • Clinical Research Alliance, Inc.

    Westbury, New York · Recruiting

  • Stefanie Spielman Comprehensive Breast Center at Olentangy River Road

    Columbus, Ohio · Recruiting

  • OHSU Research Integrity

    Portland, Oregon · Not yet recruiting

  • Rittenhouse Hematology/Oncology

    Philadelphia, Pennsylvania · Withdrawn

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Not yet recruiting

  • The Center for Cancer and Blood Disorders - Breast Center

    Fort Worth, Texas · Not yet recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Mays Cancer Center

    San Antonio, Texas · Recruiting

  • Bon Secours St. Francis Medical Oncology Center

    Midlothian, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Centro de Oncologia e Investigacion Buenos Aires COIBA

    Buenos Aires, Argentina · Not yet recruiting

  • Pergamino Clinic

    Buenos Aires, Argentina · Not yet recruiting

  • Centro de Investigaciones Médicas y Desarrollo LC

    Buenos Aires, Argentina · Not yet recruiting

  • Fleischer Medical Center (Centro Medico Fleischer)

    Buenos Aires, Argentina · Not yet recruiting

  • Fundacion Respirar

    Buenos Aires, Argentina · Not yet recruiting

  • Centro Oncológico Korben

    Buenos Aires, Argentina · Not yet recruiting

  • Alexander Fleming Institute

    Buenos Aires, Argentina · Not yet recruiting

  • Center for Medical Education and Clinical Research (CEMIC)

    Buenos Aires, Argentina · Not yet recruiting

  • Cordoba Oncology Institute (IONC)

    Córdoba, Argentina · Not yet recruiting

  • Fundación CORI

    La Rioja, Argentina · Not yet recruiting

Showing 40 of 239 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.